相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety and efficacy of interleukin-6-receptor inhibitors in the treatment of neuromyelitis optica spectrum disorders: a meta-analysis
Sanjeev Kharel et al.
BMC NEUROLOGY (2021)
Complete Relief of Painful Tonic Seizures in Neuromyelitis Optica Spectrum Disorder by Satralizumab Treatment
Akiyuki Uzawa et al.
INTERNAL MEDICINE (2021)
Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review
Paul M. Elsbernd et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)
Early Initiation of Tocilizumab Treatment Against Moderate-to-Severe Myelitis in Neuromyelitis Optica Spectrum Disorder
Chen Du et al.
FRONTIERS IN IMMUNOLOGY (2021)
Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies
Edgar Carnero Contentti et al.
JOURNAL OF NEUROINFLAMMATION (2021)
Optical Coherence Tomography Reveals Longitudinal Changes in Retinal Damage Under Different Treatments for Neuromyelitis Optica Spectrum Disorder
Pei Zeng et al.
FRONTIERS IN NEUROLOGY (2021)
Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders
D. M. Paton
DRUGS OF TODAY (2021)
Satralizumab in the treatment of neuromyelitis optica spectrum disorder
Ankelien Duchow et al.
NEURODEGENERATIVE DISEASE MANAGEMENT (2021)
The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody
Romana Hoeftberger et al.
ACTA NEUROPATHOLOGICA (2020)
Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations
Yang Mao-Draayer et al.
NATURE REVIEWS NEUROLOGY (2020)
Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study
Yoshiki Takai et al.
BRAIN (2020)
Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders
Ankelien Duchow et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Efficacy of tocilizumab for fulminant multiple sclerosis with a tumefactive cervical lesion: A 12-year-old boy
Hiroki Hoshino et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
Anthony Traboulsee et al.
LANCET NEUROLOGY (2020)
Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial
Chao Zhang et al.
LANCET NEUROLOGY (2020)
Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders
Itay Lotan et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Mendelian randomization study to evaluate the effects of interleukin-6 signaling on four neurodegenerative diseases
Haihua Zhang et al.
NEUROLOGICAL SCIENCES (2020)
Reader Response: Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases
Carolin Schwake et al.
ANNALS OF NEUROLOGY (2020)
Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases
Simone Mader et al.
CURRENT OPINION IN NEUROLOGY (2020)
Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment
Fabio Giuseppe Masuccio et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
A meta-analysis to determine the efficacy and safety of tocilizumab in neuromyelitis optica spectrum disorders
QinFang Xie et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology
Kazuo Fujihara et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
Different Targets of Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders: A Meta-Analysis Evidenced From Randomized Controlled Trials
Tao Xue et al.
FRONTIERS IN NEUROLOGY (2020)
Off-label use of tocilizumab in neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases: A case-series
J. Rigal et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Serum level of IL-1β in patients with inflammatory demyelinating disease: Marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD)
Young Nam Kwon et al.
JOURNAL OF NEUROIMMUNOLOGY (2020)
Tocilizumab treatment in severe recurrent anti-MOG-associated optic neuritis
Helen Hayward-Koennecke et al.
NEUROLOGY (2019)
Two Cases of Pediatric AQP4-Antibody Positive Neuromyelitis Optica Spectrum Disorder Successfully Treated with Tocilizumab
Markus Breu et al.
NEUROPEDIATRICS (2019)
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
Takashi Yamamura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options
Nicolas Collongues et al.
DRUGS (2019)
Myelin oligodendrocyte glycoprotein antibodies in neurological disease
Markus Reindl et al.
NATURE REVIEWS NEUROLOGY (2019)
Blockade of IL-6 signaling in neuromyelitis optica
Manabu Araki
NEUROCHEMISTRY INTERNATIONAL (2019)
Tocilizumab in MOG-antibody spectrum disorder: a case report
G. Novi et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
What You Need to Know About AQP4, MOG, and NMOSD
Sashank Prasad et al.
SEMINARS IN NEUROLOGY (2019)
Investigational drugs in development to prevent neuromyelitis optica relapses
Friedemann Paul et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
CSF cytokine profile in MOG-IgG plus neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications
Kimihiko Kaneko et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)
Interleukin-6: designing specific therapeutics for a complex cytokine
Christoph Garbers et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis
Nadja Borisow et al.
FRONTIERS IN NEUROLOGY (2018)
Cytokines and Tissue Damage Biomarkers in First-Onset Neuromyelitis Optica Spectrum Disorders: Significance of Interleukin-6
Yuzhen Wei et al.
NEUROIMMUNOMODULATION (2018)
Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic
Remi A. Kessler et al.
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2016)
Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders
Ingo Kleiter et al.
NEUROTHERAPEUTICS (2016)
Treatment of rheumatoid arthritis during pregnancy: present and future
Frauke Forger et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2016)
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin
Sven Jarius et al.
JOURNAL OF NEUROINFLAMMATION (2016)
Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan
Ken Nakajima et al.
MODERN RHEUMATOLOGY (2016)
MS arising during Tocilizumab therapy for rheumatoid arthritis
Philippe Beauchemin et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data
Maria Hoeltzenbein et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2016)
MS arising during Tocilizumab therapy for rheumatoid arthritis
Philippe Beauchemin et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Anti-IL-6 neutralizing antibody modulates blood-brain barrier function in the ovine fetus
Jiyong Zhang et al.
FASEB JOURNAL (2015)
Analysis of the treatment of neuromyelitis optica
Jose Torres et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2015)
Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study
Eiichi Tanaka et al.
MODERN RHEUMATOLOGY (2015)
Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece
Kostas Athanasakis et al.
RHEUMATOLOGY INTERNATIONAL (2015)
Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder
Marius Ringelstein et al.
JAMA NEUROLOGY (2015)
Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?
Alberto Gajofatto et al.
WORLD JOURNAL OF CLINICAL CASES (2015)
Update on biomarkers in neuromyelitis optica
Esther Melamed et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)
Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS
Sung-Min Kim et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)
Cytokines and Chemokines in Neuromyelitis Optica: Pathogenetic and Therapeutic Implications
Akiyuki Uzawa et al.
BRAIN PATHOLOGY (2014)
Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab
Manabu Araki et al.
Modern Rheumatology (2014)
Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients
Liene Elsone et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders
Douglas Kazutoshi Sato et al.
NEUROLOGY (2014)
Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica A pilot study
Manabu Araki et al.
NEUROLOGY (2014)
Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK
Alex Diamantopoulos et al.
PHARMACOECONOMICS (2014)
IL-6 in Inflammation, Immunity, and Disease
Toshio Tanaka et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks
Akiyuki Uzawa et al.
CLINICA CHIMICA ACTA (2013)
Cytokine profile in relapsing-remitting multiple sclerosis patients and the association between progression and activity of the disease
Ana Paula Kallaur et al.
MOLECULAR MEDICINE REPORTS (2013)
Disease Amelioration With Tocilizumab in a Treatment-Resistant Patient With Neuromyelitis Optica Implication for Cellular Immune Responses
Bernd C. Kieseier et al.
JAMA NEUROLOGY (2013)
Interleukin 6 Receptor Blockade in Patients With Neuromyelitis Optica Nonresponsive to Anti-CD20 Therapy
Ilya Ayzenberg et al.
JAMA NEUROLOGY (2013)
Treatment of neuromyelitis optica: an evidence based review
Douglas Sato et al.
ARQUIVOS DE NEURO-PSIQUIATRIA (2012)
Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflammatory Diseases
Toshio Tanaka et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2012)
Serum level of interleukin-6 in Chinese patients with multiple sclerosis
Ying-Chun Chen et al.
JOURNAL OF NEUROIMMUNOLOGY (2012)
Notable Increased Cerebrospinal Fluid Levels of Soluble Interleukin-6 Receptors in Neuromyelitis Optica
Honghao Wang et al.
NEUROIMMUNOMODULATION (2012)
Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy
Alexander Diamantopoulos et al.
JOURNAL OF MEDICAL ECONOMICS (2012)
Treatment of neuromyelitis optica: Review and recommendations
Dorlan J. Kimbrough et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2012)
Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica
Norio Chihara et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Enhanced IL-6 Production in Aquaporin-4 Antibody Positive Neuromyelitis Optica Patients
Sema Icoz et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2010)
Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6
Akiyuki Uzawa et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis
Akiyuki Uzawa et al.
JOURNAL OF NEUROLOGY (2009)
Interleukin-6 Blockade Suppresses Autoimmune Arthritis in Mice by the Inhibition of Inflammatory Th17 Responses
Minoru Fujimoto et al.
ARTHRITIS AND RHEUMATISM (2008)
IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis
Satoshi Serada et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Guidelines on the use of intravenous immune globulin for neurologic conditions
Tom Feasby et al.
TRANSFUSION MEDICINE REVIEWS (2007)
Increased T-lymphocyte interleukin-6 binding in patients with multiple sclerosis
P Bongioanni et al.
EUROPEAN JOURNAL OF NEUROLOGY (2000)
IL-6 is required for the development of Th1 cell-mediated murine colitis
M Yamamoto et al.
JOURNAL OF IMMUNOLOGY (2000)
分享论文
